Evidence map›Paper›PMID 28532151›Full record

ArticleACS chemical neuroscience2018

Biotinylated Bioluminescent Probe for Long Lasting Targeted in Vivo Imaging of Xenografted Brain Tumors in Mice.

Yu Lin Jiang, Yun Zhu, Alfred B Moore, Kayla Miller, Ann-Marie Broome

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. PreventingACS applied materials & interfaces · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yu Lin JiangDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, §Neurosciences, ‡Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina 29425, United States.
Yun ZhuDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, §Neurosciences, ‡Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina 29425, United States.
Alfred B MooreDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, §Neurosciences, ‡Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina 29425, United States.
Kayla MillerDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, §Neurosciences, ‡Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina 29425, United States.
Ann-Marie BroomeDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, §Neurosciences, ‡Hollings Cancer Center, Medical University of South Carolina , Charleston, South Carolina 29425, United States.ORCID 0000-0002-2384-5212
Medical University of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
NCI NIH HHS P30 CA138313
6 · The paper itself

Abstract

Bioluminescence is a useful tool for imaging of cancer in in vivo animal models that endogenously express luciferase, an enzyme that requires a substrate for visual readout. Current bioluminescence imaging, using commonly available luciferin substrates, only lasts a short time (15-20 min). To avoid repeated administration of luciferase substrate during cancer detection and surgery, a long lasting bioluminescence imaging substrate or system is needed. A novel water-soluble biotinylated luciferase probe, B-YL (1), was synthesized. A receptor-targeted complex of B-YL with streptavidin (SA) together with a biotinylated epidermal growth factor short peptide (B-EGF) (SA/B-YL/B-EGF = 1:3:1, molar ratio) was then prepared to demonstrate selective targeting. The complex was incubated with brain cancer cell lines overexpressing the EGF receptor (EGFR) and transfected with the luciferase gene. Results show that the complex specifically detects cancer cells by bioluminescence. The complex was further used to image xenograft brain tumors transfected with a luciferase gene in mice. The complex detects the tumor immediately, and bioluminescence lasts for 5 days. Thus, the complex generates a long lasting bioluminescence for cancer detection in mice. The complex with selective targeting may be used in noninvasive cancer diagnosis and accurate surgery in cancer treatment in clinics in the future.

Indexed as

Luminescent AgentsLuminescent MeasurementsAnimalsBiotinylationBrain NeoplasmsCell Line, TumorEpidermal Growth FactorHumansLuciferases, FireflyMice, NudeOligopeptidesStreptavidinTime FactorsTransfectionEpidermal Growth FactorLuciferases, FireflyLuminescent AgentsOligopeptidesStreptavidinbioluminescenceepidermal growth factorGlioblastomain vivo imaging

Identifiers

PMID28532151
PMCPMC5947857
OpenAlexW2620177088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.